PHS
RGNX icon

PFM Health Sciences’s Regenxbio RGNX Stock Holding History

PFM Health Sciences’s Portfolio RGNX Stock Details RGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-793,951
Closed -$23.7M – 122
2018
Q1 		$23.7M Buy
793,951
+24,156
+3% +$703K 0.48% 65
2017
Q4 		$25.6M Buy
+769,795
New +$23.2M 0.61% 58
2017
Q3 		– Sell
-271,603
Closed -$5.36M – 104
2017
Q2 		$5.36M Sell
271,603
-526,644
-66% -$10.2M 0.14% 83
2017
Q1 		$15.4M Buy
798,247
+299,662
+60% +$5.78M 0.39% 72
2016
Q4 		$9.25M Buy
498,585
+211,346
+74% +$4.04M 0.26% 81
2016
Q3 		$4.02M Buy
+287,239
New +$3.17M 0.12% 82
2016
Q1 		– Sell
-119,092
Closed -$1.98M – 91
2015
Q4 		$1.98M Buy
119,092
+11,787
+11% +$234K 0.06% 66
2015
Q3 		$2.36M Buy
+107,305
New +$2.74M 0.07% 63

Other funds holding RGNX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
WM
WS Management Jacksonville, Florida $1.13B AUM 53.44% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

PFM Health Sciences's RGNX Position: Q2 2018 in Review

PFM Health Sciences sold out of Regenxbio (RGNX) in Q2 2018, closing a stake of 793,951 shares — an estimated $23.7M sold.

PFM Health Sciences first reported a position in RGNX in Q3 2015 and held it in 8 quarters. The position peaked at $25.6M in Q4 2017. 177 funds tracked by Wall St. Rank hold RGNX as of Q2 2018.

  • PFM Health Sciences reported no remaining Regenxbio position as of Q2 2018 after selling out during the quarter.
  • PFM Health Sciences sold 793,951 Regenxbio shares in Q2 2018, an estimated $23.7M.
  • PFM Health Sciences first reported a position in Regenxbio in Q3 2015 and held it in 8 quarters.
  • PFM Health Sciences's Regenxbio position peaked at $25.6M in Q4 2017.
  • 177 funds tracked by Wall St. Rank held Regenxbio as of Q2 2018.

Based on PFM Health Sciences's 13F filing for Q2 2018, filed 14 Aug 2018.